Patient preferences for treatment of basal cell carcinoma: Importance of cure and cosmetic outcome

Acta Dermato-Venereologica

Volumn 96, Issue 3, 2016, Pages 355-360

  Martin, Isabelle ^a   Schaarschmidt, Marthe Lisa ^a   Glocker, Anne ^a   Herr, Raphael ^b   Schmieder, Astrid ^a   Goerdt, Sergij ^a   Peitsch, Wiebke K ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Basal cell carcinoma; Conjoint analysis; Cosmetic outcome; Discrete choice; Excision; Patient preferences

Indexed keywords

FLUOROURACIL; IMIQUIMOD;

AGED; ANESTHESIA; ARTICLE; BASAL CELL CARCINOMA; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER THERAPY; CARBON DIOXIDE LASER; CRYOSURGERY; CURETTAGE; ESTHETICS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT PREFERENCE; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RECURRENCE RISK; WOUND CLOSURE; WOUND HEALING; ATTITUDE TO HEALTH; CARCINOMA, BASAL CELL; DECISION MAKING; ECONOMICS; HEALTH CARE COST; MIDDLE AGED; PSYCHOLOGY; REMISSION; RISK FACTOR; SKIN NEOPLASMS; SOCIOECONOMICS; TREATMENT OUTCOME; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, BASAL CELL; CHOICE BEHAVIOR; FEMALE; HEALTH CARE COSTS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATIENT PREFERENCE; REMISSION INDUCTION; RISK FACTORS; SKIN NEOPLASMS; SOCIOECONOMIC FACTORS; TREATMENT OUTCOME; WOUND HEALING;

EID: 84959122300     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-2273     Document Type: Article

References (43)

1. Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. Adv Exp Med Biol 2014; 810: 120-140.
2. Trakatelli M, Morton C, Nagore E, Ulrich C, Del Marmol V, Peris K, el al. Update of the European guidelines for basal cell carcinoma management. Eur J Dermatol 2014; 24: 312-329.
3. Lomas A, Leonardi-Bee J, Bath-Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol 2012; 166: 1069-1080.
4. Madan V, Lear JT, Szeimies RM. Non-melanoma skin cancer. Lancet 2010; 375: 673-685.
5. Perera E, Gnaneswaran N, Staines C, Win AK, Sinclair R. Incidence and prevalence of non-melanoma skin cancer in Australia: A systematic review. Australas J Dermatol 2015 Feb 25. [Epub ahead of print].
6. Jung GW, Metelitsa AI, Dover DC, Salopek TG. Trends in incidence of nonmelanoma skin cancers in Alberta, Canada, 1988-2007. Br J Dermatol 2010; 163: 146-154.
7. Tan ES, Ee M, Shen L, Chua H, Chan YH, Tan SH. Basal cell carcinoma in Singapore: a prospective study on epidemiology and clinicopathological characteristics with a secondary comparative analysis between Singaporean Chinese and Caucasian patients. Australas J Dermatol 2015; 56: 175-179.
8. Leverkus M. Malignant epithelial tumors: part I. Pathophysiology and clinical features. J Dtsch Dermatol Ges 2012; 10: 457-471.
9. Walther U, Kron M, Sander S, Sebastian G, Sander R, Peter RU, et al. Risk and protective factors for sporadic basal cell carcinoma: results of a two-centre case-control study in southern Germany. Clinical actinic elastosis may be a protective factor. Br J Dermatol 2004; 151: 170-178.
10. Karagas MR, Zens MS, Li Z, Stukel TA, Perry AE, Gilbert-Diamond D, et al. Early-onset basal cell carcinoma and indoor tanning: a population-based study. Pediatrics 2014; 134: e4-12.
11. McCusker M, Basset-Seguin N, Dummer R, Lewis K, Schadendorf G, Sekulic A, et al. Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease. Eur J Cancer 2014; 50: 774-783.
12. Bath-Hextall FJ, Perkins W, Bong J, Williams HC. Interventions for basal cell carcinoma of the skin. Cochrane Database Syst Rev 2007 Jan 24; 1: CD003412.
13. Mulvaney PM, Higgins HW 2nd, Dufresne RG Jr, Cruz AP, Lee KC. Basal cell carcinomas of the ear are more aggressive than on other head and neck locations. J Am Acad Dermatol 2014; 70: 924-926.
14. Puig S, Berrocal A. Management of high-risk and advanced basal cell carcinoma. Clin Transl Oncol 2015; 17: 497-503.
15. Smeets NW, Krekels GA, Ostertag JU, Essers BA, Dirksen CD, Nieman FH, et al. Surgical excision vs Mohs’ micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet 2004; 364: 1766-1772.
16. Sekulic A, Mangold AR, Northfelt DW, LoRusso PM. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway. Curr Opin Oncol 2013; 25: 218-223.
17. Cirrone F, Harris CS. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma. Clin Ther 2012; 34: 2039-2050.
18. Breuninger H, Sebastian G, Kortmann RD, Schwipper V, Werner J, Garbe C. Brief guidelines: basal cell carcinoma of the skin. J Dtsch Dermatol Ges 2006; 4: 441-443.
19. Bahner JD, Bordeaux JS. Non-melanoma skin cancers: photodynamic therapy, cryotherapy, 5-fluorouracil, imiquimod, diclofenac, or what? Facts and controversies. Clin Dermatol 2013; 31: 792-798.
20. Manousaridis I, Leverkus M. Malignant epithelial tumors: part II. Therapy and prevention. J Dtsch Dermatol Ges 2013; 11: 9-25.
21. Kwasniak LA, Garcia-Zuazaga J. Basal cell carcinoma: evidence-based medicine and review of treatment modalities. Int J Dermatol 2011; 50: 645-658.
22. Essers BA, Dirksen CD, Prins MH, Neumann HA. Assessing the public’s preference for surgical treatment of primary basal cell carcinoma: a discrete-choice experiment in the south of the Netherlands. Dermatol Surg 2010; 36: 1950-1955.
23. Tinelli M, Ozolins M, Bath-Hextall F, Williams HC. What determines patient preferences for treating low risk basal cell carcinoma when comparing surgery vs imiquimod? A discrete choice experiment survey from the SINS trial. BMC Dermatol 2012; 12: 19.
24. Weston A, FitzGerald P. Discrete choice experiment to derive willingness to pay for methyl aminolevulinate photodynamic therapy versus simple excision surgery in basal cell carcinoma. Pharmacoeconomics 2004; 22: 1195-1208.
25. Schaarschmidt ML, Umar N, Terris D, Goebler M, Goerdt S, Peitsch WK. Patient preferences for psoriasis treatments: process characteristics can outweigh outcome attributes. Arch Dermatol 2011; 147: 1285-1294.
26. Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ 2000; 320: 1530-1533.
27. Jan S, Mooney G, Ryan M, Bruggemann K, Alexander K. The use of conjoint analysis to elicit community preferences in public health research: a case study of hospital services in South Australia. Aust N Z J Public Health 2000; 24: 64-70.
28. Marshall DA, Johnson FR, Phillips KA, Marshall JK, Thabane L, Kulin NA. Measuring patient preferences for colorectal cancer screening using a choice-format survey. Value Health 2007; 10: 415-430.
29. Damen TH, de Bekker-Grob EW, Mureau MA, Menke-Pluijmers MB, Seynaeve C, Hofer SO, et al. Patients’ preferences for breast reconstruction: a discrete choice experiment. J Plast Reconstr Aesthet Surg 2011; 64: 75-83.
30. Orme BK. Getting started with conjoint analysis: strategies for product design and pricing research, 2nd edn. Madison, WI: Research Pub LLC, 2009.
31. Ryan M, Scott DA, Reeves C, Bate A, van Teijlingen ER, Russell EM, et al. Eliciting public preferences for healthcare: a systematic review of techniques. Health Technol Assess 2001; 5: 1-186.
32. Scott A. Identifying and analysing dominant preferences in discrete choice experiments: an application in health care. J Econ Psychol 2002; 23: 383-398.
33. Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma: a systematic review. Arch Dermatol 2009; 145: 1431-1438.
34. Telfer NR, Colver GB, Morton CA. Guidelines for the management of basal cell carcinoma. Br J Dermatol 2008; 159: 35-48.
35. Hauschild A, Breuninger H, Kaufmann R, Kortmann RD, Schwipper V, Werner J, et al. Short German guidelines: basal cell carcinoma. J Dtsch Dermatol Ges 2008; 6 Suppl 1: S2-4.
36. Morton CA, Szeimies RM, Sidoroff A, Braathen LR. European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications-actinic keratoses, Bowen’s disease, basal cell carcinoma. J Eur Acad Dermatol Venereol 2013; 27: 536-544.
37. Kibarian MA, Hruza GJ. Nonmelanoma skin cancer. Risks, treatment options, and tips on prevention. Postgrad Med 1995; 98: 39-40.
38. Arits AH, Mosterd K, Essers BA, Spoorenberg E, Sommer A, De Rooij MJ, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, noninferiority, randomised controlled trial. Lancet Oncol 2013; 14: 647-654.
39. Ozolins M, Williams HC, Armstrong SJ, Bath-Hextall FJ. The SINS trial: a randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma. Trials 2010; 11: 42.
40. Grewal SK, Chren MM, Parvataneni R, Stuart SE, Galles E, Linos E. “What is it about your skin cancer that bothers you the most?” 700 patients respond. Br J Dermatol 2015; 173: 296-297.
41. Lee EH, Klassen AF, Nehal KS, Cano SJ, Waters J, Pusic AL. A systematic review of patient-reported outcome instruments of nonmelanoma skin cancer in the dermatologic population. J Am Acad Dermatol 2013; 69: e59-67.
42. Asgari MM, Bertenthal D, Sen S, Sahay A, Chren MM. Patient satisfaction after treatment of nonmelanoma skin cancer. Dermatol Surg 2009; 35: 1041-1049.
43. Galles E, Parvataneni R, Stuart SE, Linos E, Grewal S, Chren MM. Patient-reported outcomes of electrodessication and curettage for treatment of nonmelanoma skin cancer. J Am Acad Dermatol 2014; 71: 1026-1028.